# Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy > **NIH NIH R41** · NEURAEGIS, INC. · 2023 · $489,268 ## Abstract Abstract Epilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed as an anti-epileptogenic agent, in part because of the limited understanding of the processes involved in the development of epilepsy. It is generally accepted that up to 50% of all epileptic patients become epileptic as a result of a triggering initial injury such as status epilepticus, stroke or traumatic brain injury. This initial triggering injury has been postulated to activate a cascade of events leading to further seizures, increased brain damage and self-propagation. Calpains are a family of soluble calcium-dependent proteases, which have been implicated in epilepsy, since they are activated by seizures and participate in neuronal damage. Recent studies have also indicated that during early epileptogenesis, seizure occurrence, calpain activity and neuronal damage are correlated, and that treatment with a non-selective calpain inhibitor reduces the development of spontaneous recurrent seizures (SRS) in the pilocarpine model of epilepsy in rats. Our laboratory has demonstrated that calpain-1 and calpain-2, two of the major calpain isoforms in the brain, have opposite functions in the brain. We have also found that calpain-2 conditional knock-out mice with calpain-2 deletion in excitatory neurons from the forebrain show normal seizure activity following injections of repeated low doses of kainic acid (KA) but exhibit no brain inflammation, degeneration and cognitive impairment in hippocampus-dependent learning 7 days after seizures. Similar protective results were obtained when wild-type mice were treated daily and for seven days after seizures with a selective calpain-2 inhibitor. These results strongly support the hypothesis that calpain-2 might represent a potential therapeutic target to prevent various pathological consequences of seizures. This Phase I STTR is directed at first determining whether a selective calpain-2 inhibitor, NA-184, might prevent the appearance of SRSs or reduce their frequency in two mouse models of epilepsy, the repeated low doses of kainic acid (KA) or of pilocarpine models (Aim #1). In Aim # 2, we will test the effects of intranasal administration of NA-184 on KA- and pilocarpine-induced neuropathology, as intranasal delivery of a variety of anti-epileptic drugs is increasingly used in the clinic. In Phase II of this STTR, we will further pursue the development of intranasal delivery of NA- 184 as an anti-epileptic treatment. NeurAegis is a small biotech company focusing on the development of selective calpain-2 inhibitors for the treatment of acute neuronal injury, including traumatic brain injury and repeated conc... ## Key facts - **NIH application ID:** 10696598 - **Project number:** 1R41NS130825-01A1 - **Recipient organization:** NEURAEGIS, INC. - **Principal Investigator:** MICHEL BAUDRY - **Activity code:** R41 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2023 - **Award amount:** $489,268 - **Award type:** 1 - **Project period:** 2023-09-01 → 2025-05-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10696598 ## Citation > US National Institutes of Health, RePORTER application 10696598, Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy (1R41NS130825-01A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10696598. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*